CD59 and cancer: Based on the tumor-independent reduction of GTAs previously reported in CRC patient serum [17], their age-related reduction in the general population [18], and their structural resemblance to the inflammation-resolving protectins and resolvins, we hypothesized that GTAs might represent a novel endogenous cancer-protective metabolic system.